Pathological characteristics and prognosis of very young patients with early breast cancer: a comparative analysis with older patients
DOI:
https://doi.org/10.2340/1651-226X.2026.45584Abstract
Background and purpose: It has generally been established that younger breast cancer patients exhibit unfavorable biology and poorer prognosis. However, previous studies have not consistently demonstrated differences between younger and older patients. The objective of this study, therefore, was to compare pathological characteristics and prognosis in young patients (age ≤ 40 years) with early breast cancer with those of older patients (age ≥ 55 years).
Patients/material and methods: Individuals diagnosed with early breast cancer (age ≤ 40 years) and those ≥ 55 years of age, who were treated at two hospitals between June 2003 and December 2019, were identified. Oncological outcomes, including recurrence-free survival (RFS), distant RFS (DRFS), and locoregional RFS (LRRFS), were compared between two groups. Kaplan–Meier survival curves and the Cox proportional hazards model were used to evaluate.
Results: Data from 288 young (≤ 40 years) and 830 older (≥ 55 years) patients were included. Pathologically, younger patients exhibited a higher prevalence of high-grade tumors. There was no significant difference in RFS and DRFS between the younger and older patient groups (RFS: hazard ratio 1.11 [95% confidence intervals (CI) 0.74–1.66]; P = 0.613; DRFS: hazard ratio 1.03 [95% CI 0.65–1.62]; P = 0.897). However, LRRFS was unfavorable in younger patients (hazard ratio, 2.15; 95% CI, 1.03–4.49; P = 0.043). Subgroup analysis revealed a significant difference in LRRFS among hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients (hazard ratio 4.04 [95% CI 1.17–13.97]; P = 0.027); however, no significant difference was observed in other subtypes.
Interpretation: Younger patients with breast cancer exhibited a higher frequency of high-grade tumors, although no differences were observed in RFS and DRFS. However, locoregional recurrence was more common among younger patients, especially HR-positive/HER2-negative breast cancer.
Downloads
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. DOI: https://doi.org/10.3322/caac.21834
Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33(5):315–18. DOI: https://doi.org/10.1016/j.canep.2009.10.003
Green M, Raina V. Epidemiology, screening and diagnosis of breast cancer in the Asia–Pacific region: current perspectives and important considerations. Asia Pac J Clin Oncol. 2008;4(s3):S5–13. DOI: https://doi.org/10.1111/j.1743-7563.2008.00191.x
Azim HA, Jr., Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16(4):427. DOI: https://doi.org/10.1186/s13058-014-0427-5
Guzmán-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ, et al. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2022;126(2):302–9. DOI: https://doi.org/10.1038/s41416-021-01597-2
Kheirelseid EH, Boggs JM, Curran C, Glynn RW, Dooley C, Sweeney KJ, et al. Younger age as a prognostic indicator in breast cancer: a cohort study. BMC Cancer. 2011;11:383. DOI: https://doi.org/10.1186/1471-2407-11-383
Haffty BG, Choi DH, Goyal S, Silber A, Ranieri K, Matloff E, et al. Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. Ann Oncol. 2009;20(10):1653–9. DOI: https://doi.org/10.1093/annonc/mdp051
Malone KE, Daling JR, Neal C, Suter NM, O’Brien C, Cushing-Haugen K, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000;88(6):1393–402. DOI: https://doi.org/10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P
Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341–7. DOI: https://doi.org/10.1016/j.jamcollsurg.2008.12.001
Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009;4(11):e7695. DOI: https://doi.org/10.1371/journal.pone.0007695
Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol. 2010;21(10):1974–81. DOI: https://doi.org/10.1093/annonc/mdq072
Azim HA, Jr., Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18(5):1341–51. DOI: https://doi.org/10.1158/1078-0432.CCR-11-2599
Owrang M, Copeland RL, Jr., Ricks-Santi LJ, Gaskins M, Beyene D, Dewitty RL, Jr., et al. Breast cancer prognosis for young patients. In Vivo. 2017;31(4):661–8. DOI: https://doi.org/10.21873/invivo.11109
Lian W, Fu F, Lin Y, Lu M, Chen B, Yang P, et al. The impact of young age for prognosis by subtype in women with early breast cancer. Sci Rep. 2017;7(1):11625. DOI: https://doi.org/10.1038/s41598-017-10414-x
Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011;117(8):1602–11. DOI: https://doi.org/10.1002/cncr.25746
Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol. 2013;31(21):2692–8. DOI: https://doi.org/10.1200/JCO.2012.44.1956
Sheridan W, Scott T, Caroline S, Yvonne Z, Vanessa B, David V, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat. 2014;147(3):617–29. DOI: https://doi.org/10.1007/s10549-014-3125-1
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN guidelines® insights: breast cancer, version 4.2023. J Natl Compr Cancer Netw. 2023;21(6):594–608. DOI: https://doi.org/10.6004/jnccn.2023.0031
Li J, Zhou J, Wang H, Liu Z, Fan Z, Liu Y, et al. Trends in disparities and transitions of treatment in patients with early breast cancer in China and the US, 2011 to 2021. JAMA Netw Open. 2023;6(6):e2321388. DOI: https://doi.org/10.1001/jamanetworkopen.2023.21388
Lin CH, Chuang PY, Chiang CJ, Lu YS, Cheng AL, Kuo WH, et al. Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. Oncologist. 2014;19(6):583–91. DOI: https://doi.org/10.1634/theoncologist.2014-0047
Kim J, Hong S, Lee JJ, Won YJ, Lee ES, Kang HS, et al. Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry. Breast Cancer Res Treat. 2021;187(3):785–92. DOI: https://doi.org/10.1007/s10549-021-06107-9
Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2017;69(3):313–17. DOI: https://doi.org/10.1007/s13304-017-0424-1
Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477–95. DOI: https://doi.org/10.3322/caac.21863
Park YH, Lee SJ, Jung HA, Kim SM, Kim MJ, Kil WH, et al. Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: single institutional experience in Korea. Breast. 2015;24(3):213–17. DOI: https://doi.org/10.1016/j.breast.2015.01.012
Shin DS, Lee J, Kang E, Noh D, Cheun JH, Lee JH, et al. Age and late recurrence in young patients with ER-positive, ERBB2-negative breast cancer. JAMA Netw Open. 2024;7(11):e2442663. DOI: https://doi.org/10.1001/jamanetworkopen.2024.42663
Copson E, Eccles B, Maishman T, Gerty S, Stanton L, Cutress RI, et al. Prospective observational study of breast cancer treatment outcomes for UK women aged 18–40 years at diagnosis: the POSH study. J Natl Cancer Inst. 2013;105(13):978–88. DOI: https://doi.org/10.1093/jnci/djt134
Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL, Klauber-DeMore N, et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol. 2011;29(1):e18–20. DOI: https://doi.org/10.1200/JCO.2010.28.9199
de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van de Velde CJ. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer. 2006;42(3):351–6. DOI: https://doi.org/10.1016/j.ejca.2005.10.006
Chang JH, Shin KH, Ahn SD, Park HJ, Chie EK, Kim JH, et al. Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy. Breast Cancer Res Treat. 2018;169(3):507–12. DOI: https://doi.org/10.1007/s10549-018-4707-0
Wang S, Wen G, Tang Y, Yang Y, Jing H, Wang J, et al. Effectiveness of the AJCC 8th edition staging system for selecting patients with T1-2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions. BMC Cancer. 2020;20(1):792. DOI: https://doi.org/10.1186/s12885-020-07267-5
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009. DOI: https://doi.org/10.1056/NEJMoa021967
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26. DOI: https://doi.org/10.1056/NEJMoa041588
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Youri Park, Yeonjoo Kwon, Jung Ho Park, Sanghwa Kim, Young Ah Lim, Hee-Joon Kang, Doyil Kim, Janghee Lee
This work is licensed under a Creative Commons Attribution 4.0 International License.
